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One possible event in the development of cancer is a disturbed
induction of apoptosis, i.e. programmed cell death. This will lead to
an enlarged population of target cells for the subsequent events,
finally leading to the fully malignant phenotype. The classical
example of this mechanism, eventually resulting in follicular
B-cell non-Hodgkin’s lymphomas, is the outcome of a transloca-
tion of chromosome 18 band q21 and chromosome 14 band q32.
This translocation places Bcl2 under control of the IgH promoter,
leading to overexpression, and subsequent inhibition of apoptosis
(Tsujimoto et al, 1984). More recently, an alternative and intriguing
mechanism has been reported in B-cell lymphomas of mucosa-
associated lymphoid tissue (MALT lymphomas). Bcl10, a gene
mapped to chromosome 1 band P22, encodes a protein with
caspase activity, which is involved in the execution of the apoptotic
machinery. Translocation of this gene to chromosome 14 band q32,
as has been found in MALT lymphomas, results in a disrupted
caspase activity, thereby preventing apoptosis (Willis et al, 1999).
Interestingly, aberrations within this gene, like point-mutations and
small deletions, were also found in a variety of cancers, including
colon cancers, mesotheliomas and testicular germ cell tumours of
adolescents and adults (TGCTs). In total, 87 cell lines were
screened for aberrations, 81 on genomic DNA level, and six using
cDNA clones. The high incidence of aberrations in Bcl10 found,
for example, in three out of three TGCT-derived cell lines, suggests
that inactivation of this gene is a general and crucial mechanism in
the pathogenesis of different types of malignancies.
TGCTs are the most common malignancy in young Caucasian
males aged between 15 and 45 years (Swerdlow, 1998), and the
incidence is still increasing. It has generally been accepted that
these cancers originate from an early germ cell, of which the
malignant counterpart is referred to as carcinoma in situ
(Skakkebæk, 1972; Jørgensen et al, 1997). Histologically and
clinically, TGCTs are divided into non-seminomatous-TGCTs
(NS-TGCTs) and seminomas (Ulbright, 1993). While seminomas
mimic carcinoma in situ, the NS-TGCTs reflect embryonal
development to a certain extent. They can be composed of
embryonal carcinoma, being the undifferentiated cells, or tera-
toma, mimicking somatic differentiation. In addition, the extra-
embryonal elements yolk sac tumour and choriocarcinoma can be
found. Total DNA content analysis showed that all TGCTs,
including carcinoma in situ, are aneuploid (Oosterhuis et al, 1989;
De Graaff et al, 1992). Karyotyping, allelic imbalances analysis
and, more recently, comparative genomic hybridization revealed a
relatively consistent pattern of gains and losses (Mathew et al,
1994; Van Echten-Arends et al, 1995; Sandberg et al, 1996;
Looijenga and Oosterhuis, 1999, and references cited therein). For
example, loss of (part of) the short arm of chromosome 1 has been
found both in seminomas and NS-TGCTs, suggesting the presence
of a tumour suppressor gene.
To investigate the suggested role of Bcl10 in the development of
TGCTs more extensively, we studied a series of derived and
related cell lines, as well as primary tumours for genomic aberra-
tions within exon 2 and 3 of this gene. Therefore we applied the
technique of single-strand conformation polymorphism (SSCP)
analysis, as well as a more straightforward analysis for a number
of reported aberrations by restriction endonuclease digestion
analysis.
MATERIALS AND METHODS
The NS-TGCT-derived cell lines Tera-1, Tera-2, GCT44, 2102 EP,
NTera-2, GCT27 and NCCIT, were included. In addition, the cell
lines Haz and Bos, derived from two extragonadal germ cell
tumours, were studied (Sinke et al, 1994; Van Echten-Arends et al,
1995), as well as the cell line S2, of which the origin is still a
matter of debate (Von Keitz et al, 1994; Andrews et al, 1996). The
mesothelioma-derived cell line M25 was also investigated
(Versnel et al, 1989). The cell lines were cultured as described
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Correspondence to: LHJ Looijengabefore (Andrews et al, 1996). Four primary testicular seminomas
and four NS-TGCTs, with the histology of pure embryonal carci-
noma, pure teratoma, pure yolk sac tumour and mixed containing
embryonal carcinoma, teratoma and yolk sac tumour, were investi-
gated. In addition, one gonadoblastoma (reviewed in Hussong
et al, 1997), one Leydig cell tumour and one spermatocytic semi-
noma (reviewed in Rosenberg et al, 1998) were studied. The
tumours were snap-frozen upon orchidectomy. Peripheral blood
DNA of three unrelated individuals were included in every experi-
ment as control, and all experiments were done at least twice.
DNA was isolated from the in vitro cultured cell lines, peripheral
blood and tumours using standard procedures as described before
(Sambrook et al, 1989).
Exons 2 and 3 were screened for the presence of aberrations on
genomic DNA level by SSCP and restriction endonuclease diges-
tion analysis on polymerase chain reaction (PCR)-amplified
fragments. Positions within the genomic sequence of the primers
used for amplification are schematically represented in Figure 1
and are identical to those described (Willis et al, 1999).
Amplification was done in a total volume of 25 ml of buffer
(10 mM Tris–HCl pH 8.8, 50 mM potassium chloride, 0.1% Triton
X-100, 2 mM magnesium chloride; 5 pmol of each primer; 0.2 mM
dNTP and 1 U Taq (Promega, Madison, WI, USA)), containing
25 ng high molecular weight DNA. The PCR programme
consisted of an initial denaturation of 4 min at 94°C, 35 cycles of
1 min at 94°C denaturation, 1 min at 60°C annealing and 1 min
at 72°C elongation, respectively, followed by 6 min at 72°C.
SSCP was carried out at 4°C on a 6% non-denaturing polyacry-
lamide gel using radioactive labelled PCR fragments. Briefly, 1 ml
of a-32P-dATP (ICN, Zoetermeer, The Netherlands) was added to
the PCR-mix and, after amplification, 25 ml sequencing loading
buffer was added. After denaturation, 4 ml was loaded on the gel
and run for 5 h at 60 Watt, whereafter the gel was dried. BioMax
film (Kodak, Rochester, NY, USA) was exposed overnight at
–80°C. To exclude misinterpretation of the SSCP patterns due to
the presence of double-stranded DNA fragments, non-denatured
PCR fragments were included.
To confirm the absence of specific aberrations, endonuclease
restriction digestion analysis was done on amplification products
of (part of) exon 2 by the primer sets as given in Figure 1 (either
exon 2 or exon 2.1, which is the same primer set as used for SSCP
analysis; see above). Therefore 5 ml PCR product was digested
with 1 unit of StuI or TaqI according to the manufacturer’s instruc-
tions (Pharmacia Biotech, Uppsala, Sweden) in a total volume of
10 ml. After digestion, the samples were run on a 2% agarose gel
stained with ethidium bromide and analysed using the IS-500
digital imaging system and AlphaImager 2000 (Alpha Innotech,
San Leandro, CA, USA). Aberrations within the recognition sites
of these specific restriction endonucleases will result in the pres-
ence of undigested fragments.
Direct sequencing of amplified fragments of exon 2 and 2.1 using
end-labelled primers 2.1r and 2.2r (Figure 1) was performed using
the cycle-sequencing kit (Perkin-Elmer Cetus, Norwalk, CT, USA).
RESULTS
To screen DNA isolated from NS-TGCT-derived and related cell
lines, as well as primary testicular tumours, including both semi-
nomas and NS-TGCTs, for aberrations within exon 2 and 3 of the
Bcl10 gene, initially SSCP was performed. For both exons, two
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Primers:  2.1f 2.2f  2.1r  2.2r  3.1f  3.2f  3.1r  3.2r
exon 2 (289) exon 3 (>381)
58G-A 172C-T
172C-G
274C-T 499insT 653C-T
262 (exon 3.1)
257 (exon 3.2)
457 (exon 3) 417 (exon 2)
244 (exon 2.2)
236 (exon 2.1)
TGA
mutations
PCR products
79 157
338
192 44
225
Restriction analysis
(wild type only) Stu I
Taq I
Figure 1 Screening strategy for aberrations within exons 2 and 3 of the Bcl10 gene. Exons are denoted at the top by rectangles (not on scale; size in bp is
given between brackets); the primers are represented by arrows and reported mutations either by triangle (truncation) or square (mis-sense). The code used for
DNA origin is as follows: white = Tera-2 (cDNA mutations, one within the StuI recognition site), grey = Tera-1 (within the TaqI recognition site), and black =
GCT44 (within TaqI recognition site). The 3¢ untranslated region is given by a hatched box. Horizontal bold bars represent the amplified fragments, as well as
fragments obtained after restriction endonuclease digestion (either StuI or TaqI) of the wild-type sequence (sizes in bp). The amplified exon 2.1 fragment is 236
bp in length instead of the 200 bp as indicated before (Willis et al, 1999). This is confirmed by analysis of the length of the fragment obtained by primers
2.1f–2.2r, giving rise to a 417 bp fragment and not a 381 bp as deduced from the data by Willis et al (1999)sets of primers were used, resulting in two overlapping fragments,
designated 2.1, 2.2, 3.1 and 3.2 respectively (see Figure 1). The
expected sizes are indicated in the Figure. In contrast to the
reported length of 200 bp (Willis et al, 1999), the 2.1 fragment is
found to be 236 bp, both in controls, cell lines and tumours. Direct
sequencing of the amplification products demonstrated that a 54
bp (and not 18 bp) intronic sequence separates the 2.1 forward
primer and exon 2 (see Figure 2 for the additional sequence). All
cell lines and tumours showed a similar SSCP pattern, identical to
the pattern detected in the control samples (not shown). The pres-
ence of double-stranded fragments, possibly leading to misinter-
pretation, was excluded within the protocol. Within the series of
NS-TGCT-derived cell lines screened in this study, Tera-1 and
GCT44 were also investigated (see Materials and Methods), and
were not found to contain aberrations on the genomic DNA level,
although these cell lines were shown to contain mutations in the
original study by Willis et al (1999; see Fig. 1).
To exclude that the presence of specific aberrations within exon
2 remained undetected by SSCP, as can be the case (Landegren et
al, 1998), we additionally performed a more direct analysis.
Therefore restriction endonuclease digestions were performed
on the amplification products of exon 2 (both 2 and 2.1) using StuI
and TaqI (see Figure 1). These restriction endonucleases digest
the wild-type sequence, resulting in fragments of respectively
79 + 157 and 79 + 338 bp for StuI, depending on the primer sets
applied, and 192 + 44 and 192 + 225 bp for TaqI respectively. In
case of a mutation within either the StuI or TaqI recognition site,
an undigested fragment of 236 or 417 bp will be found. A
disrupted StuI recognition site can be expected for Tera-2,
although this mutation was only reported in a cDNA clone. None
of the cell lines and tumours tested in this study showed the pres-
ence of undigested fragments after StuI and TaqI digestion, indi-
cating the absence of mutations within these sequences, of which
representative examples are illustrated in Figure 3. These results
were confirmed by direct sequencing of the amplification products
(data not shown). Moreover, we also studied the mesothelioma cell
line M25, found to contain a deletion of 16 bp within exon 3. In
our hands, PCR showed the wild-type length of this fragment in
this particular cell line (not shown).
DISCUSSION
Apoptosis is found to be crucial for normal development and
maintenance of an organism. In this process, caspase (‘cysteinyl
aspartate-specific proteinases’) activity is important for proper
execution. Several caspases are identified so far (Salvesen and
Dixit, 1997). In addition to its importance during normal develop-
ment and maintenance, a disturbed apoptosis has also been identi-
fied as a possible event in the development of cancer. This can be
the result of activation of apoptosis-inhibiting genes, like Bcl2, or,
more recently, also due to inactivation of apoptosis-inducing
genes. Disruption of the caspase activity of Bcl10 has most
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Figure 2 Sequence analysis of the 3-prime region of intron 1 of Bcl10. Direct sequencing of amplified products 2 and 2.1 revealed the following intronic
sequence (lower case); the forward primer 2.1f is denoted with an arrow (above), and the exon 2 sequence (GenBank AJ006288) in uppercase letters with the
nucleotide numbering underneath for orientation purposes. DNA samples analysed, i.e. Tera-1 and CGT44, only showed the wild-type sequence
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Figure 3 Representative results of the restriction enzyme digestion analysis of the amplification products of exon 2 of the Bcl10 gene with TaqI and StuI. Using
exon 2 amplified fragments (2 and 2.1) and subsequently restriction analysis with the enzymes TaqI (top) and StuI (bottom), all samples showed an identical
pattern (sizes are given on the right side with arrows) as found in the control samples denoted as Pbl (= DNA isolated from peripheral blood of healthy
individuals). Abbreviations used: U = undigested PCR products; D = digested PCR products. M: DNA size marker pUC Mix (2 ml (100 ng); Fermentas, Vilnius,
Lithuania); sizes are given on the left siderecently been found in MALT lymphomas (Willis et al, 1999). In
addition, this study also identified mutations within exons 2 and 3
of this gene in a variety of cancers of different origin, including
three out of three NS-TGCT-derived cell lines. It is of note, that we
suggested inhibition of apoptosis being one of the mechanisms
involved in the pathogenesis of TGCTs, i.e. lack of induction of
apoptosis of the precursor cell of this cancer (Looijenga and
Oosterhuis, 1999). Moreover, we showed that RAS mutation or
amplification leads to an enhanced in vitro survival of seminoma
cells, related to a reduced sensitivity for apoptosis upon disruption
of the micro-environment (Oosterhuis et al, 1998; Looijenga and
Oosterhuis, 1999).
To study the role of Bcl10 in the pathogenesis of TGCTs in more
detail, we performed in principle a similar approach as Willis et al
(1999). DNA of a series of cell lines were investigated by SSCP
using the same primer sets as reported before. However, no indica-
tions for the presence of aberrations within exons 2 and 3 were
obtained in our hands. The presence of independent and multiple
controls without denaturation before SSCP prevented misinterpreta-
tion of the data due to double-stranded fragments in the samples
under investigation. Besides the cell lines, a series of primary
TGCTs also showed no aberrant bands by SSCP. In fact, even no
aberrant migration patterns of the fragments derived from the cell
lines Tera-1 and GCT44 were observed, in spite of the results
reported before (Willis et al, 1999). In addition, the restriction
endonuclease digestion analysis for specific sequence abnormali-
ties, also showed no undigested fragment, i.e. only wild-type alleles
were amplified, which was confirmed by direct sequencing. There is
no reason to assume the inability of amplification of mutant alleles,
because of the use of flanking sets of primers (see Figure 1).
Because in the initial study the majority of aberrations were detected
on the genomic DNA level, we limited our survey to genomic DNA
analysis. The formerly reported mutations in the cDNA clones of the
Tera-2 cell line could not be confirmed by us on genomic DNA.
Theoretically, the discrepancies between the study of Willis et al
(1999) and our results (this study) could be due to the extended in
vitro culturing of the different cell lines, both from NS-TGCT- and
mesothelioma-origin. Indeed, we have found other differences
between clones derived from the same parental cell line, which
were cultured in different laboratories for extended periods of time
(Looijenga et al, 1997). However, assuming that inactivation by
aberrations at the genomic DNA level of Bcl10 is important in the
development of TGCTs, which could be lost upon in vitro growth,
these aberrations should have been present in primary TGCTs.
Although we only screened a limited number of seminomas and
NS-TGCTs, no indications were obtained for the presence of
mutations within this gene, not with SSCP nor by restriction
endonuclease digestion analysis.
Although still of putative interest in general, our results specifi-
cally question the role of inactivation of Bcl10 in the development
of TGCTs. We conclude that lack of induction of apoptosis due to
loss of caspase activity by genomic events in TGCTs is not
involved in the majority of cases, if at all.
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